This collection will give you access to many of the sessions recorded at the 2019 AMP Annual Meeting & Expo presentations, the pre-meeting Molecular Pathology Outreach Course, and the associated pdf slides (see the topics tab for a complete list of available talks). CME, CMLE, and SAMs is available for select sessions in this collection. 


 

AMP is the leading organization in the field of molecular diagnostics, and the AMP Annual meeting is the premier gathering of molecular professionals. As technologies change and new challenges arise, members and non-members alike rely on the AMP meeting to obtain the critical information needed to ensure that their patients receive the best care and best results.

Many of the sessions from the AMP 2019 Annual Meeting and Expo were recorded and this collection contains all the recorded sessions and downloadable PDF slides. See the "topics" tab for a list of all the presentations for which recordings and slides are available.

Duration: 61.25 hours total

You can purchase individual session recordings ($15-$50 for members, $63-$189 for nonmembers) or ALL of the AMP 2019 Annual Meeting Recordings which also includes the pre-meeting Molecular Pathology Outreach Course for a significant discount ($450 for members, $649 for nonmembers).

  • To purchase all the session recordings, click the "Add to Basket" button located on the right.
  • To purchase individual talks, click on the "Purchase Individual Topics" button on the right, click on the titles to expand, and select the "add" button for the session(s) that you would like to purchase.

If you have questions, please email AMPeducation@amp.org


CME, CMLE, and SAMs is available for some of the recorded content. See the topics tab or click here to see which talks are available for CE.

Credit Type

Maximum Number of Credit Hours

CME/CMLE

maximum of 57.50 hrs

SAM

maximum of  37.50 hrs
Continuing Education Credit must be purchased and claimed by December 24, 2022

* You may not submit SAMs and CME/CMLE credit for the same content.

CE Information

Physicians

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Association for Molecular Pathology.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this enduring material for a maximum of 57.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

CMLE

This activity has been planned and implemented in accordance with Amedco and the joint provider-ship of the American Society for Clinical Pathology (ASCP) and the Association for Molecular Pathology (AMP). ASCP CMLE credit hours are acceptable for the ASCP Board of Certification Maintenance Program (CMP). Course number 5045.

American Board of Pathology Self-Assessment Credit

This course is valid for up to 37.50 of SA-CME Self-Assessment credits (SAMs). Learners should self-submit these credits to their boards.


No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.


Join the AMP Family for a discount on this item.

Course Information
Course Date:
November 07, 2019
Click on a topic name to see details and purchase options.
Thursday November 7, 2019

AMP Annual Meeting 2019 - Program Book

Also available here: https://amp19.amp.org/program/program/

Not Available for Individual Purchase

Detection of  Outbreaks and Unusual Pathogen using AI and Machine Learning

Amy Leber, PhD, Nationwide Childrens Hospital, Columbus, OH, USA

Use of Machine Learning Algorithms to Support Clinical Microbiology Culture Interpretation

Karissa Culbreath, PhD, TriCore Reference Laboratories, Albuquerque, NM, USA

Session Description: The future is now? From pre-analytical to post-analytical there are many opportunities to deploy artificial intelligence in the clinical microbiology laboratory. The question is, are we really ready for it? This session will describe the basic concepts of artificial intelligence and its use in the clinical microbiology laboratory.

Session Objectives:

  • Describe applications of artificial intelligence and machine learning in interpretation of digital images in microbiology.
  • Describe applications of artificial intelligence and machine learning in predicting the presence of infections and guiding laboratory testing.

Duration: 1.00 hr

Recording Date: November 7, 2019

CME/CMLE credit: 1.00 hr

SAM credit: Not available

Last day to purchase course and CE claim creditDecember 24, 2022

ProductAddPrice
CulbrethLeber
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Ultra-hypermutated Pediatric Glioblastoma of Lynch Syndrome Mimicking Constitutional Mismatch Repair Deficiency Syndrome

Chen Yang, MD, PhD, Virginia Commonwealth University, Richmond, VA, USA

A Case of T-PLL with EZH2 Mutation; EZH2 the Sword or the Shield?

Panieh Terraf, PhD, Harvard Medical School - Brigham and Women's Hospital, Boston, MA, USA

Exome Reanalysis in a Patient with a Somatic CN-LOH in 17p and TP53 Mutation, and a Germline DNAJC21 Biallelic Mutation Associated with Myelodysplastic Susceptibility

Elan Hahn, MD, University of Toronto, Toronto, Ontario, Canada

Somatic Mosaic IDH1 Mutation in a Case of Maffucci Syndrome

Diana Bryk, MD, New York Presbyterian - Columbia, New York, NY, USA

Session Description: Challenging Case Studies are presented by trainees or technologists. They will discuss the case's clinical history, molecular analysis, interesting features, and the proposed diagnosis. Other molecular testing methods, if applicable, will be included in the presentation, including biopsies, gross/microscopic pathology, immunohistochemistry/flow cytometry, and cytogenetic findings.

Session Objectives:

  • Describe the context of a challenging clinical case.
  • Discuss the molecular pathology techniques used in the diagnosis of the case.
  • Propose a final diagnosis based upon findings and diagnostic evidence.

Duration: 0.75 hr

Recording Date: November 7, 2019

CME/CMLE credit: 0.75 hr

SAM credit: Not available

Last day to purchase course and claim CE credit:December 24, 2022

ProductAddPrice
GENETICS CS
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

A Surprising Finding in Primary Cutaneous CD8-positive Aggressive Epidermotropic Cytotoxic T-cell Lymphoma

Mark Evans, MD, University of California, Irvine, Orange, CA, USA

Clonal Selection Following FLT3 Tyrosine Kinase Inhibitor Treatment for Acute Myeloid Leukemia

Adam Fisch, MD, PhD, Brigham and Women's Hospital, Boston, MA, USA

Identification of a Cryptic ABL1 Rearrangement in a Refractory Acute Myeloid Leukemia Patient with Diploid Karyotype by Conventional Cytogenetics

Arash Ronaghy, MD, PhD, MD Anderson Cancer Center, Houston, TX, USA

Muddy Waters: A Report of Granulocytes Infusion Confounding Next-Generation Sequencing Interpretation

Tareq Qdaisat, MD, University of Nebraska Medical Center, Omaha, NE, USA

Session Description: Challenging Case Studies are presented by trainees or technologists. They will discuss the case's clinical history, molecular analysis, interesting features, and the proposed diagnosis. Other molecular testing methods, if applicable, will be included in the presentation, including biopsies, gross/microscopic pathology, immunohistochemistry/flow cytometry, and cytogenetic findings.

Session Objectives:

  • Describe the context of a challenging clinical case.
  • Discuss the molecular pathology techniques used in the diagnosis of the case.
  • Propose a final diagnosis based upon findings and diagnostic evidence.

Duration: 0.75 hr

Recording Date: November 7, 2019

CME/CMLE credit: 0.75 hr

SAM credit: Not available

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
CSHeme1
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Compound EGFR and BRAF variants in NSCLC against the backdrop of suspected MEN2A

Jeremy Adler, MD, Pennsylvania Hospital, UPHS, Philadelphia, PA, USA

Expanded Next Generation Sequencing Panel Detects A Rare EGFR Kinase Domain Duplication In A Patient with Metastatic Lung Cancer

Jong Kim, MD, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Pitfalls in Identification of Mismatch Repair Deficiency: An Unusual Pulmonary Intimal Sarcoma.

Wanying Zhang, MD, New York Presbyterian Hospital, New York, NY, USA

EGFR-Mutated Lung Adenocarcinoma with Early Resistance to Osimertinib

Brennan Decker, MD, PhD, Brigham and Women's Hospital, Boston, MA, USA

 

Session Description: Challenging Case Studies are presented by trainees or technologists. They will discuss the case's clinical history, molecular analysis, interesting features, and the proposed diagnosis. Other molecular testing methods, if applicable, will be included in the presentation, including biopsies, gross/microscopic pathology, immunohistochemistry/flow cytometry, and cytogenetic findings. 

Session Objectives: 

  • Describe the context of a challenging clinical case. 
  • Discuss the molecular pathology techniques used in the diagnosis of the case. 
  • Propose a final diagnosis based upon findings and diagnostic evidence.

Duration: 1.00 hr

Recording Date: November 7, 2019

CME/CMLE credit: 1.00 hr

SAM credit: Not available

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Solid Tumor CS
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Russell Higuchi, PhD, Cepheid, Sunnyvale, CA, USA

Session Description: Making the most out of the least has long been a requirement for the practical application of molecular biology. The technology arc of my career from recombinant DNA to Ancient DNA to PCR to forensic DNA to pathogen detection to Next-Generation Sequencing – has been anchored in this consistent need to deal with samples with limited nucleic acid content. In describing this arc, I will present a personal journey that shows, with respect to getting the most information from our samples, how far we’ve come over the course of my career. I will also describe the early, heady days of PCR and the invention of real-time PCR, the application of real-time PCR to real-world problems (including those of the developing world) and my recent work on making PCR faster on existing instruments.

Session Objectives:

  • Describe the history of sensitive DNA detection and sequence identification.
  • Provide a review of the principles of real-time PCR detection and quantification.
  • Look forward to better, faster and cheaper molecular diagnostic tools.

Duration: 1.00 hr

Recording Date: November 7, 2019

CME/CMLE credit: 1.00 hr

SAM credit: Not available

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Higuchi
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Targeting Immune Signaling Checkpoints in Acute Myeloid Leukemia

Ivana Gojo, MD, Johns Hopkins, Baltimore, MD, USA

Choosing Patient Therapy with Dynamic BH3 Profiling

Anthony Letai, MD, PhD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA USA

Diverse Mechanisms of Acquired Resistance to CAR T Cell Immunotherapy

Andrei Thomas-Tikhonenko, PhD, Children's Hospital of Philadelphia, Philadelphia, PA, USA

Session Description: Novel nonchemotherapeutic agents have revolutionized treatment of hematological malignancies, especially in clinical settings where therapeutic options are limited. This is evidenced by accelerated FDA approval of BCL2 inhibitor, and ever expanding field of immunotherapeutics using checkpoint inhibitors and CAR-T cells. As we gain more knowledge, molecular laboratories will play a crucial role in identification on biomarkers of sensitivity and resistance to these agents for optimal implementation of precision medicine. This session will discuss the latest updates on the clinical utility, mechanisms of resistance, and innovative state-of-the-art strategies to assess responses in leukemia.

Session Objectives:

  • Describe the sensitivity and resistance patterns to immune check point inhibitors in AML and MDS.
  • Understand the potential utility of dynamic BH3 profiling as a functional precision medicine tool.
  • Understand the mechanisms of resistance to CD19-directed immunotherapies in B-lymphoblastic leukemias.

Duration: 1.50 hr

Recording DateNovember 7, 2019

CME/CMLE credit: 1.50 hr

SAM credit: 1.50 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
GojoLetaiThomas-Tikhonenko
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Rapid DNA: From Research to Field

Amanda Sozer, PhD, SNA International, Washington, DC, USA

Basics of Genetic Genealogy and Its Impact on Forensic Investigation

Howard Cash, Gene Codes Corporation, Ann Arbor, MI, USA

Session Description: "Recreational genealogy" has been aggressively marketed in recent years, sometimes by commercial companies that sequence and analyze DNA for a belowcost price to participants, and then further analyze and aggregate data for license to third party researchers. We know from history that genetic information can and has been abused. This is one reason why uses of law enforcement's DNA databases has been carefully limited by the laws that created them. However, these protections are less potent than they were only a few years ago; Public and private genealogy databases are not controlled by the same legislation, policies and case law. Recent developments in use of STR analysis and DNA sequencing methods for human identification in both humanitarian efforts following mass fatalities, human trafficking and for identification of perpetrators of violent crime will be reviewed. Combining DNA results with genealogical data has led to identification of suspects in scores of criminal investigations in the past 18 months. This new field of genealogics demonstrates the power of these new methods and at the same time raises both policy and privacy questions which will be addressed.

Session Objectives:

  • Understand the role of STR analysis and DNA sequencing for humanitarian identification efforts, mass fatalities and forensic investigations.
  • Understand how to evaluate some of the main scientific, legal, and policy implications of using DNA sequencing in forensic medicine.
  • Understand the application of DNA technology to forensics and the identification of suspects involved in crimes.

Duration: 1.50 hr

Recording Date: November 7, 2019

CME/CMLE credit: 1.50 hr

SAM credit: Not available

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Sozer_Cash
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Getting More from your MiSeq with DASH and FLASH

Emily Crawford, PhD, Chan Zuckerberg Biohub, San Francisco, CA USA

Assessing Unintended Off-Target Mutations Caused by Cas9 and Other Gene Editing Enzymes

Vikram Pattanayak, MD, PhD, Massachusetts General Hospital, Boston, MA, USA

Session Description: The rapid developing of CRISPR/Cas mediated gene-editing technologies is an immensely powerful research tool with remarkable promise to revolutionize the future therapy for genetic diseases, cancer, and sensitive nucleic acid detection, diagnosis of infectious diseases and beyond. Despite the increasing maturity of CRISPR-Cas9 technology, its safety and efficiency are important concerns requiring comprehensive studies. Clinical translation of the CRISPR-Cas9 system is hampered by off-target alterations. In infectious disease diagnosis, metagenomic Next Generation Sequencing (mNGS) has emerged as a promising technology for global detection of pathogens in clinical samples. However, standard methods are often not sensitive enough to detect critical sequences like those responsible for antimicrobial resistance. Novel approaches (DASH and FLASH) based on the programmability of the CRISPR/Cas9 system to increase coverage of desired organisms and genes can result in increased assay sensitivity.

Session Objectives:

  • Describe the basic functions of the CRISPR/Cas9 system.• Discuss the benefits and limitations of metagenomic Next Generation Sequencing (mNGS) for infectious disease diagnostics.
  • Discuss the application of CRISPR technology as a diagnostic tool for infectious diseases.

Duration: 1.50 hr

Recording Date: November 7, 2019

CME/CMLE credit: 1.50 hr

SAM credit: 1.50 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
CrawfordPattanayak
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Clinical Implementation of Pharmacogenomics

Philip Empey, PharmD, PhD, University of Pittsburgh, UPMC, Pittsburg, PA, USA

What’s New in Pharmacogenetics?

Victoria M. Pratt. PhD, Indiana University School of Medicine, Indianapolis, IN, USA

Session Description: Many healthcare professionals (e.g., laboratorians, physicians, physician assistants, pharmacists, nurses and genetic counselors) believe pharmacogenomics (PGx) is essential to personalized medicine; however, many still lack confidence prescribing, dosing, interacting with other healthcare professionals and counseling patients with regard to PGx. This session will explore the current evidence, regulatory, reimbursement and best practice recommendations in PGx testing. Keys to successful implementation and emerging large pharmacogenomics initiatives will be discussed with a focus on contemporary issues in the field.

Session Objectives:

  • Recognize the availability of evidence-based PGx resources to inform prescribing.
  • Describe the key characteristics of PGx alleles that are recommended for inclusion in clinical testing panels by the AMP.
  • Understand successful implementation approaches and barriers to increased PGx clinical testing

Duration: 1.25 hr

Recording Date: November 7, 2019

CME/CMLE credit: 1.25 hr

SAM credit: 1.25 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Empey_Pratt
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Anthony Sireci, MD, Loxo Oncology, Stamford, CT, USA

Aaron Bossler, MD, PhD, University of Iowa, Iowa City, IA, USA

Demystifying Molecular testing coverage and policies: MolDX and Medicare

Gabriel Bien-Willner. MD, PhD, Palmetto GBA, TX, USA

Session Description: Understanding the processes for coding, pricing and coverage determination is at the heart of getting reimbursed for the clinical molecular procedures we perform. This panel will review those processes and hear insights from a Medical Director for the Palmetto Medicare Administrative Contractor to help members understand the intent and breadth of the molecular procedure codes, understand how coverage policies and procedures affect determination of payment or nonpayment including the National Coverage Determination for NGS testing, and discuss the pricing process and the impact of PAMA on laboratory pricing. The three presentations will be followed by a panel discussion and Q&A session.

Session Objectives:

  • Understand current test coding and define tier 1 molecular pathology CPT codes.
  • Understand how coverage polices determine payment or nonpayment.• Understand and describe the impact of PAMA on laboratory pricing.

Duration: 1.25 hr

Recording Date: November 7, 2019

CME/CMLE credit: 1.25 hr

SAM credit: 1.25 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Sireci_Bossler_Bien-Willner
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Kimberle Chapin, MD, Brown Biology and Medicine, Providence, RI, USA

The Art of Navigating Molecular Infectious Disease Test Results: From Ordering To Application In the Clinical Setting

Sejal Morjaria, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Session Description: The increased availability of rapid molecular infectious disease diagnostics has significantly improved the potential for clinical laboratories to impact patient outcomes. Appropriate and optimal use of these new tests require communication and partnership between clinical microbiologists and clinicians. In the session, two speakers, a microbiologist and infectious disease clinician will discuss various approaches to diagnostic stewardship in a case format.

Session Objectives:

  • Define the concept of diagnostic stewardship.
  • List key stakeholders in establishing diagnostic stewardship.
  • Describe approaches to establishing diagnostic stewardship.

Duration: 1.25 hr

Recording Date: November 7, 2019

CME/CMLE credit: 1.25 hr

SAM credit: Not available

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Chapin_Morjaria
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Perspective on Establishing a Biorepository for Clinical and Research Use

Kristy Crooks, PhD, University of Colorado, Aurora, CO, USA

Profiling the DNA Damage Repair Capacity of High Grade Serous Ovarian Tumors using Patient-Derived Organoids

Sarah Hill, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, USA

Session Description: Recent cost reduction in genetic testing and advances in analytics have enabled the successful establishment of several large-scale biorepositories collecting samples linked to phenotype and health data. Health systems, universities, and private organizations are increasingly investing in biobanking as a means to foster research, develop commercial partnerships, reduce healthcare costs, and improve brand visibility. Additionally, organizations are leveraging biobank resources to return clinical genetic test results to participants. This session will explore the advantages and pitfalls common to emerging biobank initiatives in the context of regulatory requirements, research endeavors, and personalized medicine.

Session Objectives:

  • Describe the potential of 3D-organoids technology for clinical applications in infectious diseases, genetic diseases, tumor modeling and biobanking.
  • Review the importance and clinical utility of biobanks.
  • Discuss the regulatory aspects of maintaining a CLIA certified biobank and the return of results in a clinical setting.

Duration: 1.00 hr

Recording Date: November 7, 2019

CME/CMLE credit: 1.00 hr

SAM credit: 1.00 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Crooks_Hill
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Big Data and Little Patients: Targeted Sequencing for Pediatric Brain Tumors

Sarah Leary, MD, MS, Seattle Children's Hospital, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Bigger is Better: More Cancer Genes in More Patients

Wendy Chung, MD, PhD, Columbia University, New York, NY, USA

Session Description: Precision oncology is increasing relying on genetic testing and laboratories frequently develop targeted tests that include hundreds of cancer-related genes. This session will highlight the relative advantages and limitations of targeted (selected gene panel) vs. comprehensive (exome and genome) genetic testing. This session will be presented as a “point-counterpoint” with each speaker focusing on the opportunities of genetic tests in molecular oncology using specific clinical applications such as pediatric brain cancer as illustrative case examples. The presentations will be followed by a panel discussion and Q&A session.

Session Objectives:

  • Discuss the benefits of next-generation sequencing in oncology.
  • Recognize the need for both targeted and comprehensive tests.
  • Describe advantages of targeted testing in pediatric oncology.

Duration: 1.00 hr

Recording Date: November 7, 2019

CME/CMLE credit: 1.00 hr

SAM credit: 1.00 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Leary_Chung
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Standing of Molecular within the Pathology/Lab Profession

Karen Kaul, MD, PhD, NorthShore University Health System, Evanston, IL, USA

Evolving Technologies and Automation

Karl Voelkerding, MD, University of Utah School of Medicine, Salt Lake City, UT, USA

Panel Discussion

Federico Monzon, MD, Castle Biosciences, Friendswood, TX, USA

Aaron Bossler, MD, PhD, University of Iowa, Iowa City, IA, USA

Yaolin Zhou, MD, Univ of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

Helen Fernandes, PhD, Columbia University Medical Center, New York, NY, USA

Session Description: This session summarizes the remarkable progress that our AMP community has made together over the society’s first 25 years. The inspiring stories we share highlight opportunities to advance your career and to promote scientific and medical progress through collaborative AMP initiatives.

Session Objectives:

  • Review the impact AMP has had on medical professionals and patients.
  • Share stories illustrating our contributions and future opportunities.

Duration: 0.75 hr

Recording Date: November 7, 2019 

Not Eligible for CME, CMLE, or SAM credit

**FREE**

Tags
free4all
ProductAddPrice
AMP 25 years
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $0.00

Using Polygenic Risk Scores (PRS) for Breast Cancer to Inform Screening: Model Fit, Calibration, and Utility

Peter Kraft, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, USA

Session Description: At this session, the definition, motivation, and development of polygenic risk scores (PRS) for breast cancer will be presented. The session will also discuss the importance of risk model calibration and the context-specific evaluation of clinical utility (balancing benefits and risks of generating and using genetic risk information in the clinic). Although the session will be focused on breast cancer screening, several general issues in the development and evaluation of PRS for other diseases in other contexts will also be highlighted.

Session Objectives:

  • Upon completion, participants will be able to understand the concept and calculation of PRS.
  • Upon completion, participants will be able to understand both clinical validity (how it is calibrated) and clinical utility (impact on clinical care) of PRS.
  • Upon completion, participants will understand the state of the science regarding PRS for breast cancer and their potential use in risk-stratified screening programs.

Duration: 1.00 hr

Recording Date: November 7, 2019

CME/CMLE credit: 1.00 hr

SAM credit: Not available

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Kraft
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00
Friday November 8, 2019

How to Validate Rare Findings - Focus on Novel Fusions

John Iafrate, MD, PhD, Massachusetts General Hospital, Boston, MA, USA

Did I Find the Right Needle in the Haystack? Sensitivity and Specificity Challenges Revealed by Ultra-accurate NGS

Rosana Risques, PhD, UW Pathology, Seattle, WA, USA

Session Description: The rapid expansion of molecular oncology testing has presented new challenges for clinical laboratories focused on developing and validating novel molecular oncology tests. Two clinical scenarios where these challenges have been notable are the RNA assays for gene fusion detection and liquid biopsy assays. The expanding role of targetable cancer gene fusions has made RNA assays that target one partner particularly appealing, but it is increasingly difficult to identify appropriate positive controls for these multiplexed assays. The advent of cell-free DNA testing in plasma has also introduced extremely rare variant detection through ultra-deep sequencing with innovative technologies and bioinformatic processing. This session will highlight the promises and pitfalls of detecting new variants in oncology and discuss strategies for how to clinically validate findings.

Session Objectives:

  • Understand the challenges associated with validating rare cancer mutations.
  • Describe validation strategies for multiplexed RNA assays.
  • Recognize the potential for ultra-low cancer-related variants in normal tissue to interfere with cell-free tumor DNA assays.

Duration: 1.00 hr

Recording Date: November 8, 2019

CME/CMLE credit: 1.00 hr

SAM credit: 1.00 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Iafrate_Risques
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Malachi Griffith, PhD, Washington University School of Medicine, St. Louis, MO, US

Session Description: Clinical interpretation of variants remains a major bottleneck for translation of genomic observations. Recognizing this need, a number of variant knowledgebases have emerged to organize efforts to synthesize complex evidence about variants and their clinical relevance. These resources differ widely in their curation approach, data sharing model, adoption of standards, overall scope and target applications. Many of these efforts remain siloed from each other. Consensus on the correct interpretation of individual variants remains elusive. To the extent that any "final" assertions emerge, their stability and reliability is largely unknown, leaving the burden of extensive vetting on the end user. In this session, the current state of the art for clinical variant knowledgebase systems and ongoing efforts to improve curation interfaces, practices, and interoperability will be discussed. Existing options such as CIViC (civicdb.org) will be used to stimulate discussion on the current state of the field, major outstanding challenges, and future directions.

Session Objectives:

  • Upon completion, participants will be able to define the concept of a knowledgebase.
  • Upon completion, participants will be able to understand the informatics aspects of developing a knowledgebase.
  • Upon completion, participants will understand the strengths and limitations of the CIViC knowledgebase and its approach to curating cancer variant interpretations from the literature.

Duration: 1.00 hr

Recording Date: November 8, 2019

CME/CMLE credit: 1.00 hr

SAM credit: 1.00 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Griffith
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Blood Group Genotyping from High Density Arrays to Whole Genomes

Bill Lane, MD, PhD, Brigham and Women's Hospital, Boston, MA, USA

Session Description: Genotyping has expanded the number of blood group antigens that can be readily typed, but it often represents a large additional testing cost. In addition, most currently available genotyping assays only target a limited number of antigens and therefore full typing of the >300 blood group is not possible. Genotyping from next generation sequencing data can in theory be used to genotype for all antigens with a known genetic basis, but early attempts required lengthy subject matter expert analysis. In addition, this manual analysis is likely error prone and not scalable for full evaluation of all 46 blood group associated genes which contain more than 2000 known antigenic allelic variants, including many structural variations. We recently developed automated software (bloodTyper) which can fully determine all genetically understood blood group antigens from whole genomes, whole exomes, and targeted next generation sequencing. Furthermore, bloodTyper was recently expanded to evaluate a cost-effective high density DNA array that targets all known blood group antigens, allowing for full blood group antigen genotyping in over 8,000 blood donors.

Session Objectives:

  • Describe the major genetic changes underlying the most commonly tested blood group antigens.
  • Describe the pros and cons between available genotyping methodologies.
  • Describe how genotyping can be used to effectively determine blood groups antigens in both donors and recipients.

Duration: 1.00 hr

Recording Date: November 8, 2019

CME/CMLE credit: 1.00 hr

SAM credit: 1.00 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Lane
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Fei Dong, MD, Brigham and Women's Hospital, Boston, MA, US

Session Description: As new targeted therapies for cancer become available, new genetic mechanisms of acquired resistance have emerged. This session discusses mechanisms of resistance to kinase inhibitors, anti-hormone therapy, PARP inhibitors, and other treatment modalities, the evolution of new strategies to overcoming resistance, and the current and anticipated value of molecular testing to aid therapy selection for patients with cancer.

Session Objectives:

  • Describe genetic mechanisms of resistance to targeted therapies, including tyrosine kinase inhibitors, anti-hormone therapies, and PARP inhibitors.
  • Interpret resistance mutations to guide patient care in the selection of second-line cancer therapies.
  • Anticipate evolving challenges and needs in molecular testing with the emergenceof resistance to current and futuretargeted therapies.

Duration: 1.0 hr

Recording Date: November 8, 2019

CME/CMLE credit: 1.00 hr

SAM credit: 1.00 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Dong
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

The Role of Lymphoma Sequencing Panel in the Diagnosis of Pediatric-Type Follicular Lymphoma

Guang Yang, MD, PhD, University of Pennsylvania, Philadelphia, PA, USA

5q- in a Patient with Chronic Myelogenous Leukemia in Accelerated Phase

James Corines, DO, SUNY Upstate Medical University, Syracuse, NY, USA

Session Description: Challenging Case Studies are presented by trainees or technologists. They will discuss the case's clinical history, molecular analysis, interesting features, and the proposed diagnosis. Other molecular testing methods, if applicable, will be included in the presentation, including biopsies, gross/microscopic pathology, immunohistochemistry/flow cytometry, and cytogenetic findings.

Session Objectives:

  • Describe the context of a challenging clinical case.
  • Discuss the molecular pathology techniques used in the diagnosis of the case.
  • Propose a final diagnosis based upon findings and diagnostic evidence.

Duration: 1.00 hr

Recording Date: November 8, 2019

CME/CMLE credit: 1.00 hr

SAM credit: Not available

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
HemeCSII
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Advances in Liquid Biopsy: Isolation, Analysis and Expansion of CTCs

Sunitha Nagrath, PhD, University of Michigan, Ann Arbor, MI, USA

Microfluidic Platforms for the Efficient Isolation of Circulating Leukemia Cells and Circulating Plasma Cells

Steven A. Soper, PhD, The University of Kansas, Lawrence, KS, USA

Session Description: New technology based on microfluidic devices are being developed for the isolation and preservation of circulating tumor cells for downstream applications, and to be able to use them to advance precision cancer medicine.

Session Objectives:

  • Understand new technology forseparation and preservation of CTCs for downstream applications.
  • Introduce a description of the new microfluidic devices being developed and describe the operational parameters of these devices for the selection of liquid biopsy markers.
  • Describe the downstream molecular information that can be garnered from the isolated markers in diseases such acute myeloid leukemia (circulating leukemia cells) and multiple myeloma (circulating plasma cells). Using liquid biopsy markers for these two diseases circumvents the need for a painful bone marrow biopsy. Information will be provided on using these liquid biopsy markers to monitor relapse from minimum residual disease, and staging patients for directing therapy (i.e., precision medicine).

Duration: 1.50 hrs

Recording Date: November 8, 2019

CME/CMLE credit: 1.50 hr

SAM credit: 1.50 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Nagrath_Soper
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

The Limitations and Consequences of Ethnicity-specific Guidelines for Carrier Screening

Dale Muzzey, PhD, Myriad Women's Health, Inc., San Francisco, CA, USA

Current Complexities and Future Directions of Expanded Carrier Screening

Nicole Faulkner, PhD, FACMGG, Invitae Corporation, San Francsico, CA, USA

Technological Advances and Detections Rates: Demystifying the Influence of Ethnicity on Carrier Detection and Residual Risk

Lisa Edelmann, PhD, Sema4, New York, NY, USA

Session Description: Carrier screening tests have been available for clinicians to order for many years. Current guidelines rely on a patient’s self-reported ethnicity, which conflates genetic and cultural factors. Common questions being asked about the future of carrier screening are: How many genes and what genes should be on Expanded Carrier Screening panels? Should we only be testing for severe/prevalent autosomal recessive disorders? Should carrier screening evolve to a healthy patient screen including pre-symptomatic gene results? How do we make complex, clinically relevant testing more accessible and digestible to the average patient? Guidelines/recommendations for expanded carrier screening relevant to residual risk estimates will be reviewed. The ambiguity, misalignment, incompleteness, deficiency, inequity, and inconsistency of current guidelines will be explored by combining a novel genetic-ancestry analysis method and several retrospective analyses on hundreds of thousands of patients tested with expanded carrier screening. Analytical detection rates of different sequencing technologies will be compared and contrasted. Calculation of residual risk estimates will be explained, and the current shortcomings will be reviewed. A path forward for guidelines that avoid current shortcomings will be elucidated.

Session Objectives:

  • Describe the original intent of carrier screening and current challenges for the laboratory.
  • Understand how to calculate residual risk after a negative carrier screening result.
  • Explain how self-reported ethnicity is an imperfect proxy for carrier risk that measurably impairs discovery of carriers if screening is based on current guidelines.

Duration: 1.50 hrs

Recording Date: November 8, 2019

Not Eligible for CME, CMLE or SAMs

ProductAddPrice
Muzzey_Faulkner_Edelmann
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Patterns of Complex Structural Variation across Thousands of Cancer Whole Genomes

Marcin Imielinski, MD, PhD, Weill Cornell Medical College, New York, NY, USA

Identification and Characterization of Cryptic Structural Variation in Human Genomes

Ryan Mills, PhD, University of Michigan, Ann Arbor, MI, USA

Session Description: Structural variations in the form of DNA rearrangements and aneuploidies are well-known genomic alterations underlying human disease. Despite the ubiquitous nature of genome sequencing in basic research and clinical diagnostics, the mutational processes driving structural variation are yet to be well characterized. In this session, the speakers will describe the strengths of different sequencing technologies and informatics algorithms in identifying different types of genomic structural variation in both cancer and individual genomes.

Session Objectives:

  • Upon completion, participants will be able to describe the landscape of structural variation in human genomes and cancers.
  • Upon completion, participants will be able to describe features of several complex structural variant patterns commonly observed in human cancer.
  • Upon completion, participants will be able to describe the strengths and weaknesses of different sequencing techniques and algorithms in SV detection.

Duration: 1.50 hrs.

Recording Date: November 8, 2019

CME/CMLE credit: 1.50 hr

SAM credit: 1.50 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Imielinski_Mills
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Do-It-Yourself Molecular LIMS

Long P. Le, MD, PhD, Massachusetts General Hospital, Charlestown, MA, USA

Picking a LIMS System

Kristina Cusmano-Ozog, MD, Children’s National, Palo Alto, CA, USA

Development of a Laboratory Information System to Support Clinical NGS Testing

Michael Kluk, MD, PhD, Weill Cornell Medicine, New York, NY, USA

Session Description: Many of the laboratory information management systems (LIMS) in use today were originally developed with clinical pathology or anatomic pathology workflows in mind and have since been adapted to include minimal functionality for the molecular lab. With the continually increasing complexity of molecular testing along with the need for rapid delivery of results, having a LIMS in today’s molecular laboratory designed for the unique and highly-complex workflows is crucial. This session will discuss LIMS currently used by 3 U.S. medical centers offering highly-complex molecular testing and how they have overcome challenges from receiving orders, tracking samples, and managing complicated workflows, to integrated reporting of complex NGS results.

Session Objectives:

  • Discuss the role of the LIMS and the unique needs of the molecular lab.• Identify basic functionality necessary for an effective molecular LIMS.
  • Describe some options currently in use to manage complex, end-to-end molecular workflows and reports.

Duration: 1.50 hr

Recording Date: November 8, 2019

CME/CMLE credit: 1.50 hr

SAM credit: 1.50 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Le_Cusmono-Ozg_Kluk
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Mark Routbort, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, US

Session Description: Variant interpretation and classification and the generation of a test report in clinical genomics are the critical last steps of a workflow that involves major upstream bioinformatics processes. While standardized criteria for variant interpretation and classification have been developed, such criteria do not include the recognition of different technical and informatics artifacts introduced either during the wet-lab processes or by the bioinformatics algorithms. In addition, despite the broad adoption of genomic sequencing in clinical laboratories, the methods and file formats widely used in bioinformatics pipelines are not formally standardized. In this hands-on workshop session, the ‘informatics’ aspects of variant annotation, classification and interpretation will be discussed with the aid of example case files that will be available to the participants both for preview and for live review during the session as the speaker goes over the various principles of the bioinformatics pipeline.

Session Objectives:

  • Upon completion, participants will be able to understand important features that distinguish technical artifacts from valid calls.
  • Upon completion, participants will be able to understand the key concepts of variant classification and interpretation.• Upon completion, participants will have knowledge of different informatic approaches underlying variant annotation and classification.

Duration: 1.50 hrs.

Recording Date: November 8, 2019

CME/CMLE credit: 1.50 hr

SAM credit: Not available

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Routbort
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Nanopore Sequencing Comes of Age

Miten Jain, PhD, University of California Santa Cruz, Santa Cruz, CA, USA

Extreme Molecular Diagnostics

Carl Wittwer, MD, PhD, University of Utah, Salt Lake City, UT, USA

Session Description: This session is provide attendees with updates on the development and progress of Extreme PCR and Nanopore sequencing and explore their potential utility in molecular diagnostics and research.

Session Objectives:

  • Discuss how advances in sample prep, PCR and melt analysis are enabling significant reduction in total test time and the impact of Extreme PCR on molecular diagnostics.
  • Discuss the technology behind Nanopore Sequencing and understand the capabilities for direct, real-time DNA & RNA sequencing.• Understand the applications of these technologies for molecular diagnosticsand research.

Duration: 1.50 hr

Recording Date: November 8, 2019

CME/CMLE credit: 1.50 hr

SAM credit: 1.50 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Jain_Wittwer
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

ESP Molecular Pathology WG: Diagnosis and Clinical Research Reproducibility

Giorgio Stanta, MD, PhD, University of Trieste, Duino-Aurisina, Italy

Quality Assessment Experience in Brazil

Roberta Sitnik, MSc, PhD, Departamento de Patologia Clínica e Anatomia Patológica, São Paulo, Brazil

Session Description: The European Society of Pathology has a working group devoted to Molecular Pathology. This WG collaborates with several European Organizations and projects. The WG's main goal is to increase reproducibility not only for diagnosis but also for clinical research performed directly in today patients. The issues developed are pre-analytics of clinical material, standardization of methods, evaluation of intra-tumor heterogeneity and training.

Session Objectives:

  • The participants will be able to know which are the major objectives of the ESP Molecular WG.
  • The objectives of the ESP-WG are especially oriented for molecular diagnostics and clinical research. This is performed with the collaboration of several European organizations and projects.
  • The ESP proposal for pre-analytics, method standardization and intra-tumor heterogeneity will be presented.

Duration: 1.00 hr

Recording Date: November 8, 2019

CME/CMLE credit: 1.00 hr

SAM credit: Not available

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Stanta_Sitnik
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Non-invasive Prenatal Sequencing for Multiple Mendelian Monogenic Disorders using Circulating Cell-free Fetal DNA

Shashikant Kulkarni, PhD, FACMG, Baylor College of Medicine, Houston, TX, USA

Prenatal Diagnosis: The Next Generation

Mark Evans, MD, Comprehensive Genetics, New York, NY, USA

Session Description: Incredible technological advances in molecular diagnostics have enabled high resolution prenatal diagnosis. However, there has been widespread confusion as to the benefits and limitations of non-invasive prenatal screening (NIPS) as compared to diagnostic testing. NIPS has been expanded beyond detection of chromosomal abnormalities in a fetus and is increasingly used for sex chromosomal aneuploidies and microdeletions, but current methods often fail to identify multi-system developmental disorders. Our experience focusing on sequencing a panel of 30 genes for relatively common dominant disorders will be reviewed. When validated, such can herald a new beginning where detection of a comprehensive spectrum of aneuploidies, copy number variations and single gene disorders is within reach. However, the gap between the cutting edge of technology and provider understanding continues to widen - not narrow, and patients’ understanding of the difference between screening and diagnosis are similarly sub-optimal. Current reliance upon NIPS has led to an epidemic of abnormalities missed that could have been diagnosed using more expanded testing.

Session Objectives:

  • Understand the process of development and validation of non-invasive prenatal diagnosis (NIPD) and understand the value of NIPD in identifying fetal dominant monogenic disorders through clinical case vignettes.
  • Understand the multimodal improvements in capabilities for screening and diagnosis of genetic and congenital abnormalities.
  • Understand the trade-offs of accepting a non-invasive screening test versus actual diagnostic testing, including missing thousands of abnormalities each year by foregoing diagnostic testing.

Duration: 1.00 hr

Recording Date: November 8, 2019

CME/CMLE credit: 1.00 hr

SAM credit: 1.00 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Kulkarni_Evans
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Centralized Testing in Molecular Pathology via Lean Laboratory Design

John Longshore, PhD, Carolinas Pathology Group, Charlotte, NC, USA

Molecular Laboratory Organization: the University of Washington Experience

Daniel E. Sabath, MD, PhD, University of Washington School of Medicine, Seattle, WA, USA

Session Description: With the changing landscape of healthcare, clinical laboratories are under immense pressure to deliver high quality, complex results despite poor payment and reimbursement rates that often do not cover the cost of performing the tests. As a cost-savings measure, some institutions are using LEAN approaches and consolidation efforts to maximize efficiency and enable sharing of resources across molecular specialties. The advantages and disadvantages of centralized versus decentralized molecular laboratories will be explored in this session.

Session Objectives:

  • Describe differing needs of various types of molecular testing.
  • Define key areas where streamlining molecular testing is beneficial to patient care and how the LEAN approach can be applied to improve the molecular lab.
  • Discuss the implications for future molecular diagnostic laboratory needs.

Duration: 1.25 hr

Recording Date: November 8, 2019

CME/CMLE credit: 1.25 hr

SAM credit: 1.25 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Longshore_Sabath
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Nathan Ledeboer, PhD, Medical College of Wisconsin, Milwaukee, WI, USA

Frederick Nolte, PhD, Medical Univ of South Carolina, Charleston, SC, USA

Session Description: Technological advancements in molecular diagnostics for infectious diseases offer greater accuracy, portability, simplicity and cost-effectiveness. These technological advancements creative new challenges for how to best delivery these services and integrate them into laboratory medicine. Other than microbiology laboratories, should other points of service be considered. This point-counter point session will debate whether molecular testing for infectious diseases should be performed in the microbiology laboratory or can be performed throughout the clinical laboratory. Dr. Ledeboer will argue that while molecular techniques are shared among many areas of pathology, the expertise for interpretation of infectious disease testing is within microbiology. Dr. Nolte will provide the rationale and supporting arguments for decentralization of molecular infectious disease testing.

Session Objectives:

  • Describe the challenges and opportunities that advancements in molecular technology have created for delivery and integration of molecular microbiology testing into laboratory medicine.
  • Describe advantages and disadvantages of performing molecular microbiology testing in different laboratory sections.
  • Discuss how microbiologists can remain engaged with molecular microbiology testing regardless of the point of service.

Duration: 1.25 hrs

Recording Date: November 8, 2019

CME/CMLE credit: 1.25 hr

SAM credit: 1.25 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Ledeboer_Nolte
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Advances in Multiple Myeloma Genomics

Brian A. Walker, BSc, PhD, University of Arkansas for Medical Sciences, Little Rock, AR

Molecular Monitoring of Myeloma

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, USA

Session Description: The use of new genome sequencing technologies has revolutionized the field of myeloma genomics, enabling the analysis of large datasets of patient material and the identification of new genomic markers associated with disease progression and prognosis. The main new findings relating to these datasets will be presented, including the mutational landscape of myeloma, mechanisms of gene dysregulation, and the genomic abnormalities associated with poor prognosis. In addition, monitoring of patients with myeloma for therapeutic resistance and minimal residual disease will also be discussed.

Session Objectives:

  • Describe findings of genomic landscape studies in myeloma and the genetic markers which relate to prognosis.
  • Understand the main deregulated pathways involved in myeloma pathogenesis and association with therapy resistance.
  • Discuss methods of minimal residual disease monitoring in myeloma.

Duration: 1.25 hrs

Recording Date: November 8, 2019

CME/CMLE credit: 1.25 hr

SAM credit: 1.25 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Walker_Munshi
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Arturo Casadevall, MD, PhD, Johns Hopkins, Baltimore, MD, USA

Session Description: The World Health Organization (WHO) estimates that climate change will have a significant impact on human health, particularly in developing countries. In addition to the increase in the number of emerging pathogens, climate change may result in the introduction of both established and emerging pathogens in new geographic areas. A genomic based approach to global surveillance of pathogens has the potential to prevent or allow for better response to potential outbreaks and epidemics.

Session objectives:

  • Describe the impact of climate change on emerging pathogens
  • Discuss genomic approaches to global surveillance of emerging pathogen

Duration: 1.00 hr

Recording Date: November 8, 2019

CME/CMLE credit: 1.00 hr

SAM credit: Not available

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Casadevall
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00
Saturday November 9, 2019

The Skeletal Dysplasias; the Long and Short of It

Deborah Krakow, FACMG, UCLA School of Medicine, Los Angeles, CA USA

Session Description: This session reviews the identification of disease genes and biologic mechanisms that lead to the inherited osteochondrodysplasia, a group of more than 350 distinct genetic disorders. This session specifically reviews the diagnosis and natural history from prenatal detection to adulthood, of patients with FGFR related disorders including, but not limited to, achondroplasia, hypochondroplasia and thanatophoric dysplasias types I and II.

Session Objectives:

  • Recognize the radiologic differences between thanatophoric dysplasias types I and II.
  • Recognize the phenotypic impact of single base changes in the FGFR3 gene.

Duration: 1.00 hr

Recording Date: November 9, 2019

CME/CMLE credit: 1.00 hr

SAM credit: Not available

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Krakow
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Barriers to Integrating Genomics More Fully into the EHR

Brian Shirts, MD, PhD, University of Washington, Seattle, WA, USA

Session Description: Although genome sequencing is near universally adopted in human disease diagnostics, the integration of genomic testing results into the electronic health record (EHR) has lagged behind. Despite technical advances and consensus on desiderata, biological and systemic barriers prevent rapid integration of genomic data into the EHR. In this session, the speaker will describe desiderata for integrating genomic information into the EHR in a way that facilitates clinical decision support. The speaker will also describe technical advances such as those included in SMART standards and FHIR API specifications that help overcome technical barriers for integrating genomics into the EHR.

Session Objectives:

  • Upon completion, participants will be able to list four technical requirements for ntegrating genomic information into the electronic health record.
  • Upon completion, participants will be able to describe two standards or specifications that can be used to integrate genomic information into the electronic health record.
  • Upon completion, participants will be able to evaluate possible solutions to address biological and systemic barriers to integrating genomic information into the electronic health record.

Duration: 1.00 hr

Recording Date: November 9, 2019

CME/CMLE credit: 1.00 hr

SAM credit: Not available

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Shirts
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

DNA Methylation and Machine Learning in Molecular Pathology for Diagnosis and Clinical Management

Matija Snuderl, MD, NYU Langone Medical Center, New York, NY, USA

Session Description: Methylation of CpG dinucleotides is a key epigenetic regulator of gene function during development and disease. DNA methylation-based biomarkers can be useful targets in the diagnosis and prognosis of tumors. This session will focus on methods used for methylation analysis, integration of DNA methylation results with histopathology and NGS methods and clinical applications for tumor subclassification.

Session Objectives:

  • Discuss the importance of DNA methylation on gene expression and methods for analysis.
  • Identify pre-analytical variables affecting DNA methylation based classifiers
  • Integrate DNA methylation results with histopathology and next-generation sequencing methods

Duration: 0.50 hr

Recorded: November 9, 2019

CME/CMLE credit: 0.50 hr

SAM credit: 0.50 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Snuderl
AMP Regular Member: $25.00
AMP Technologist Member: $25.00
AMP Associate Member: $25.00
Non-member Price: $95.00

Opportunities and Challenges of Fungal Cell-Free DNA Testing for Diagnosis of Invasive Fungal Infection

Niaz Banaei, MD, Stanford University, Stanford, CA, USA

Detecting HPV Circulating Tumor DNA by Liquid Biopsy

Daniel Higginson, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Session Description: Liquid biopsy, the use of a liquid specimen such as blood, urine or cerebral spinal fluid to detect circulating cellfree tumor cells or DNA is increasingly being used as an alternative to invasive surgical biopsies. Oropharyngeal, cervical, and anal cancers are each associated with high risk HPV subtypes, which can either be integrated into tumor genomes or remain episomal. HPV DNA is an attractive substrate for liquid biopsy detection because one cancer cell may have many copies of HPV DNA. Emerging reports find a high sensitivity of detection and possible utility in minimal residual disease detection for these diseases. In infectious disease diagnosis, the utility of liquid biopsy for deep-seated infection is similarly being explored and reports are emerging on its applications in the detection of cell-free fungal DNA to diagnose invasive fungal infections.

Session Objectives:

  • Review the concept of liquid biopsy and cell free DNA detection for molecular diagnosis.
  • Describe applications of liquid biopsy and cell-free DNA detection for the diagnosis of fungal infections.
  • Discuss the role of HPV in oropharyngeal squamous cell cancer.

Duration: 1.00 hr

Recording Date: November 9, 2019

CME/CMLE credit: 1.00 hr

SAM credit: 1.00 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Banaei_Higginson
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

An Interesting Case Involving a CIC-NUTM1 Rearranged Epitheliod Tumor

Latrice Landry, PhD, MMSc, MS, Dana Farber Cancer Institute/ Brigham and Women's Hospital, Boston, MA, USA

Detection of Rare Fusion using Foundation One and Oncomine Tests: A Male in his 20’s with an Aggressive Orbital Tumor

Terri Jones, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

A Case of Cutaneous Lymphoma with PCM1-JAK2 Rearrangement

Talent Theparee, MD, Stanford Healthcare, Stanford, CA, USA

Microsatellites: Instability in an Apparently Stable World

Patrick Leach, BS, TriCore Reference Laboratories, Albuquerque, NM, USA

Session Description: Challenging Case Studies are presented by trainees or technologists. They will discuss the case's clinical history, molecular analysis, interesting features, and the proposed diagnosis. Other molecular testing methods, if applicable, will be included in the presentation, including biopsies, gross/microscopic pathology, immunohistochemistry/flow cytometry, and cytogenetic findings.

Session Objectives:

  • Describe the context of a challenging clinical case.
  • Discuss the molecular pathology techniques used in the diagnosis of the case.
  • Propose a final diagnosis based upon findings and diagnostic evidence.

Duration: 1.00 hr

Recording Date: November 9, 2019

CME/CMLE credit: 1.00 hr

SAM credit: Not available

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
SolidTumorCSII
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

RNA-seq for the Detection of Gene Fusions and Other Alterations in Cancer

Kevin Halling, MD, PhD, Mayo Clinic, Rochester, MN, USA

Applications of RNA-Seq in Cancer

Olena Vaske, PhD, FCCMG, University of California, Santa Cruz, CA, USA

Session Description: Transcriptome sequencing (RNA-seq) of cancer samples for expression profiling and variant and gene fusion detection is a well-established method in scientific research and a powerful and rapidly emerging tool in clinical diagnostics. Various whole-transcriptome and targeted RNA sequencing methods as well as associated informatics algorithms have been developed for RNA-seq; however, standards for RNA-seq are still evolving. In this session, the speakers will discuss the utility of RNA-seq for profiling tumor samples, including informatics approaches for splicing analysis, gene fusion detection, expressed variant detection, and gene expression analysis.

Session Objectives:

  • Upon completion, participants will be able to describe the applications of RNA-seq in cancer.
  • Upon completion, participants will be able to understand the technical challenges in standardizing RNA-seq.
  • Upon completion, participants will be able to understand the strengths and limitations of the RNA-Seq technology.

Duration: 1.00 hr

Recording Date: November 9, 2019

CME/CMLE credit: 1.00 hr

SAM credit: 1.00 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Halling_Vaske
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Bacteriome and Mycobiome Imbalance and Design of Precision Medicine and Nutrition

Mahmoud A. Ghannoum, PhD, EMBA, FIDSA,FAAM, University Hospitals Cleveland Medical

Session Description: In infectious diseases, the concept of precision medicine – the right medicine, at the right dose, for the right patient, at the right time – can be applied in various ways including the analysis of an individual patient microbiome to predict disease or health outcomes as well as in the more precise monitoring of antimicrobial resistance of pathogens. Preventing and managing the emergence of antiretroviral drug resistance is a key component of worldwide efforts to reduce antimicrobial resistance. Additionally, while many studies have focused on the characterization of the gut bacterial microbiome (bacteriome), a better understanding of the microbiome impact on patient health will need to include evaluation of other human ecosystems including the fungal microbiome (mycobiome).

Session Objectives:

  • Describe the gut Mycobiome and understand the interactions between the bacteriome and mycobiome and its consequences on health outcomes.

Duration: 0.75 hr

Recording Date: November 9, 2019

CME/CMLE credit: 0.75 hr

SAM credit: Not available

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Ghannoum
AMP Regular Member: $25.00
AMP Technologist Member: $25.00
AMP Associate Member: $25.00
Non-member Price: $95.00

What to Expect When You Find the Unexpected: Pregnancy and Incidental Findings in Noninvasive Prenatal Screening

Susan Hancock, MS, Myriad Women's Health, Salt Lake City, UT, USA

Session Description: The classic pregnancy handbook "What to Expect When You're Expecting" is widely read by patients as a means to prepare and better understand pregnancy. In a similar spirit, this session will focus on providing a resource to the laboratory professional to better understand unexpected findings that occur in noninvasive prenatal screening via cell-free DNA analysis. Attendees will gain an understanding of the nature, cause, and impact of these unexpected findings in the clinical setting. The session will also explore the most recent clinical opinions on appropriate follow-up for patients impacted by incidental findings.

Session Objectives:

  • List several incidental findings encountered in noninvasive prenatal screening (NIPS) and identify their origin.
  • Summarize the clinical conditions diagnosed subsequent to atypical NIPS results and understand the magnitude of risk based on the most recent literature.
  • Recognize health care provider attitudes toward incidental findings in the clinical setting

Duration: 0.5 hr

Recording Date: November 9, 2019

CME/CMLE credit: 0.50 hr 

SAM credit: 0.50 hr

Last day to purchase course and claim CE creditDecember 24, 2022

 

ProductAddPrice
Hancock
AMP Regular Member: $15.00
AMP Technologist Member: $15.00
AMP Associate Member: $15.00
Non-member Price: $63.00

Real-time Clinical Applications for Whole Genome Sequencing of Bacteria

Brad Cookson,MD, PhD, University of Washington, Seattle, WA, USA

Bacterial Strain Typing in the Age of Whole Genome Sequencing: Promises and Pitfalls

Richard Goering, PhD, Creighton University School of Medicine, Omaha, NE, USA

Session Description: The history and evolution of molecular approaches to bacterial strain typing and its importance for infection control and epidemiological analysis will be presented in this session. The use of next-generation, whole genome sequencing for strain typing will be discussed including the associated benefits and challenges. Applications for NGS strain typing in epidemiological investigations, infection control, public health, and patient management will also be described.

Session Objectives:

  • Learn the history and importance of molecular strain typing for epidemiological analysis and infection control.
  • Discuss the utility of NGS for investigation of hospital acquired infections.
  • Gain perspective on leveraging the power of whole genome sequencing while managing the complexities in a clinical setting.

Duration: 1.50 hrs

Recording Date: November 9, 2019

CME/CMLE credit: 1.50 hr

SAM credit: 1.50 hr 

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Cookson_Goering
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

Tumor Mutational Burden (TMB): Harmonization and Future Application

Jeff Allen, PhD, Friends of Cancer Research, Washington, DC, USA

Session Description: Tumor mutational burden (TMB) by next-generation sequencing is emerging as a biomarker of response to immunotherapy agents in cancer patients. However, heterogeneity in experimental and analytical protocols, as well as bioinformatic pipelines, influence the variability for TMB estimation and reporting, demonstrating the need for standardization and harmonization of TMB assessment methodology across assays and clinical centers. Friends of Cancer Research (Friends) and the Quality Assurance Initiative Pathology (QuIP), have collaborated to coordinate efforts for international multi-stakeholder initiatives to address this need.

Session Objectives:

  • Review TMB as a biomarker for immunotherapy response in cancer patients.
  • Describe methodologies for TMB assessment and quantification.
  • Review the many factors that influence TMB assessment.

Duration: 0.75 hr

Recording Date: November 9, 2019

CME/CMLE credit: 0.75 hr

SAM credit: 0.75 hr

Last day to purchase course and claim CE creditDecember 24, 2022

 

ProductAddPrice
Allen
AMP Regular Member: $25.00
AMP Technologist Member: $25.00
AMP Associate Member: $25.00
Non-member Price: $95.00

TMB: The Case for Understanding and Harmonizing Complex Biomarkers

Albrecht Stenzinger, MD, University Hospital Heidelberg, Heidelberg, Germany

Session Description: Tumor mutational burden (TMB) by next-generation sequencing is emerging as a biomarker of response to immunotherapy agents in cancer patients. However, heterogeneity in experimental and analytical protocols, as well as bioinformatic pipelines, influence the variability for TMB estimation and reporting, demonstrating the need for standardization and harmonization of TMB assessment methodology across assays and clinical centers. Friends of Cancer Research (Friends) and the Quality Assurance Initiative Pathology (QuIP), have collaborated to coordinate efforts for international multi-stakeholder initiatives to address this need.

Session Objectives:

  • Review TMB as a biomarker for immunotherapy response in cancer patients.
  • Describe methodologies for TMB assessment and quantification.
  • Review the many factors that influence TMB assessment

Duration: 0.75 hr

Recording Date: November 9, 2019

CME/CMLE credit: 0.75 hr

SAM credit: Not available

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Stenzinger
AMP Regular Member: $25.00
AMP Technologist Member: $25.00
AMP Associate Member: $25.00
Non-member Price: $95.00

Leveraging Human Microbiome Features to Diagnose and Stratify Children with Irritable Bowel Syndrome

James Versalovic, MD, PhD, Texas Children's Hospital, Houston, TX, USA

Session Description: The session will feature oral presentations from authors of articles featured by the Journal of Molecular Diagnostics in 2019 issues. The articles were selected based on their innovation, high importance, and impact. Diverse specialty areas of the practice of molecular diagnostics will be included.

Session Objectives:

  • Bring recognition to the scientific scope of JMD.
  • Highlight articles in the JMD which contribute significant advances to molecular pathology laboratory practice.
  • Provide opportunity to hear directly from the authors.

Duration: 0.5 hrs

Recording Date: November 9, 2019

CME/CMLE credit: 0.50 hr

SAM credit: 0.50 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Versalovic
AMP Regular Member: $15.00
AMP Technologist Member: $15.00
AMP Associate Member: $15.00
Non-member Price: $63.00

Development and Verificatin of an RNA-seq Assay for the Detection of Gene Fusions in Tumors

Kevin C. Halling, MD, PhD, Mayo Clinic, Rochester, MN, USA

Session Description: The session will feature oral presentations from authors of articles featured by the Journal of Molecular Diagnostics in 2019 issues. The articles were selected based on their innovation, high importance, and impact. Diverse specialty areas of the practice of molecular diagnostics will be included.

Session Objectives:

  • Bring recognition to the scientific scope of JMD.
  • Highlight articles in the JMD which contribute significant advances to molecular pathology laboratory practice.
  • Provide opportunity to hear directly from the authors.

Duration: 0.50 hrs

Recording Date: November 9, 2019

CME/CMLE credit: 0.50 hr

SAM credit: Not available

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Halling
AMP Regular Member: $15.00
AMP Technologist Member: $15.00
AMP Associate Member: $15.00
Non-member Price: $63.00

A Rigorous Interlaboratory Examination of the Need to Confirm NGS-detected Variants in Clinical Genetic Testing

Stephen Lincoln, Invitae, San Francisco, CA, USA

Session Description: The session will feature oral presentations from authors of articles featured by the Journal of Molecular Diagnostics in 2019 issues. The articles were selected based on their innovation, high importance, and impact. Diverse specialty areas of the practice of molecular diagnostics will be included.

Session Objectives:

  • Bring recognition to the scientific scope of JMD.
  • Highlight articles in the JMD which contribute significant advances to molecular pathology laboratory practice.
  • Provide opportunity to hear directly from the authors.

Duration: 0.5 hrs

Recording Date: November 9, 2019

Not Eligible for CME, CMLE, or SAM

ProductAddPrice
Lincoln
AMP Regular Member: $15.00
AMP Technologist Member: $15.00
AMP Associate Member: $15.00
Non-member Price: $63.00

Jeremy Segal, MD, PhD, University of Chicago, IL, USA

Ahmet Zehir, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Session Description: Each individual laboratory validates its own combination of software and thresholds for their secondary bioinformatics processes. In this session, we will have participants discuss their approaches to analyze data files from cancer sequencing studies (SEQC2). The obtained results and the analytic methods used to generate the results will be presented by each participating institution, after which, the nuances and differences in the bioinformatics analytic approach and the results will be discussed. This session is expected to be both enjoyable and informative with active discussions.

Session Objectives:

  • Upon completion, participants will be able to appreciate the complexity and difficulty in the bioinformatics analyses and interpretation of NGS data.
  • Upon competition, participants will have knowledge about different methods for analyzing somatic variation, with the understanding that there is no “one size fits all” for NGS data analysis.
  • Upon competition, participants will learn that different bioinformatics pipelines have unique advantages and complexities, and to take these into consideration when implementing them internally.

Duration: 1.25 hrs

Recording Date: November 9, 2019

CME/CMLE credit: 1.25 hr

SAM credit: Not available

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Segal_Zehir
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

G008 - Germline RAD51B loss-of-function variants confer susceptibility to hereditary breast and ovarian cancers and result in homologous recombination deficient tumors

Diana Mandelker, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

G014 - A framework of critical considerations in interpretation of NGS based tests for germline disorders - On Behalf of CLSI Document Development Committee (DDC) on Nucleic Acid Sequencing (MM09)

Avni Santani, PhD, Children's Hospital of Philadelphia, Philadelphia, PA, USA

G023 - Integrated Germline and Somatic Analysis Identifies Actionable Cancer Predisposing Germline Mutations in 9,734 Patients with Advanced Cancers

Liying Zhang, MD, PhD, Memorial Slone Kettering Cancer Center, New York, NY, USA

G036 - Significance Associated with Phenotype (SAP) Score – A Method for Ranking Genes and Genomic Regions Based on Sample Phenotype

Jianling Ji, MD, MS, Children's Hospital of Los Angeles, South Pasadena, CA, USA

G010 - A Method to Missense Madness: Improving Clinical Variant Interpretation with a Pathway-Focused Functional Assay

Sarah Brnich, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Session Description: Platform presentations of selected Genetics abstracts.

Session Objectives:

  • Analyze platform presentations of abstracts highlighted by the Genetics Subdivision leadership as particularly significant.
  • Evaluate the scientific merit and significance of these selected studies through further discussion with the authors.

Duration: 1.25 hrs

Recording Date: November 9, 2019

CME/CMLE credit: 1.25 hr

SAM credit: 1.25 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Genetics Platform Presentation
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

H034 - Identification of Neoplastic Clonal T-cell Sequences in Unrelated Healthy Individuals: Limitations of High Throughput TRG Sequencing for Minimal Residual Disease (MRD) Analysis

Siddhartha Sen, MD, PhD, Duke University Medical Center, Durham, NC, USA

H039 - Measurable Residual Disease Monitoring for Patients with Acute Myeloid Leukemia Following Hematopoietic Cell Transplantation Using Error Corrected Hybrid Capture Next Generation Sequencing

Vidya Balagopal, PhD, University of Chicago, Chicago, IL, USA

H021 - IGH locus assessment using hybrid-capture, a proof-of-concept study

Etienne Mahe, MD, MSc, FRCPC, FCAP, University of Calgary, Calgary, Alberta, Canada

H027 - Convergence on Genomic Abrogation of the DNA Damage Response Pathway in CLL is Observed in Patients with Loss of18p

Waihay Wong, Brigham and Women's Hospital and Harvard Medical School

H020 - IDH1 p.S280F mutation is potentially a novel mechanism of resistance to Ivosidenib therapy in an IDH1 positive acute myeloid leukemia

Zoltan Oltvai, MD, University of Pittsburgh, Pittsburgh, PA, USA

Session Description: Platform presentations of selected Hematopathology abstracts.

Session Objectives:

  • Analyze platform presentations of abstracts highlighted by the Hematopathology Subdivision leadership as particularly significant.
  • Evaluate the scientific merit and significance of these selected studies through further discussion with the authors.

Duration: 1.25 hr

Recording Date: November 9, 2019

CME/CMLE credit: 1.25 hr

SAM credit: 1.25 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Heme Platform Presentations
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

ID019 - Mycoplasma genitalium assay results from high and low risk populations: implications for sexually transmitted infection panel menu

Kimberle Chapin, MD, Brown Biology and Medicine, Providence, RI, USA

ID018 - Cell-free RNA is More Sensitive than DNA for the Detection of Pediatric Bacterial Sepsis via Shotgun Metagenomic Sequencing

Caitlin Dougherty, The Children's Hospital of Philadelphia, Philadelphia, PA, USA

ID020 - Clinical and Histologic Features of Patients Tested Using the BioFire FilmArray Gastrointestinal Panel

Jonathan Mowers, MD, PhD, Michigan Medicine, Ann Arbor, MI, USA

ID043 - Investigation of amplicon sequencing technology in diagnosis of drug resistant tuberculosis by testing FFPE specimens

Nanying Che, PhD, Departement of Pathology, Beijing Chest Hospitial, Medical Capital University, Beijing, China

ID003 - Microbial Cell-free DNA Sequencing for Multiplexed Detection and Quantitation of Cytomegalovirus, Epstein-Barr Virus, and BK Virus

Timothy Blauwkamp, Karius, Inc., Iowa City, CA, USA

Session Description: Platform presentations of selected Infectious Diseases abstracts.

Session Objectives:

  • Analyze platform presentations of abstracts highlighted by the Infectious Diseases Subdivision leadership as particularly significant.
  • Evaluate the scientific merit and significance of these selected studies through further discussion with the authors.

Duration: 1.25 hrs

Recording Date: November 9, 2019

CME/CMLE credit: 1.25 hr

SAM credit: 1.25 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
ID Platform Presentation
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

I031 - Platform-agnostic deployment of bioinformatics pipelines for clinical NGS assays using containers, infrastructure orchestration, and workflow manager

Sabah Kadri, PhD, Lurie Children's Hospital of Chicago, Chicago, IL, USA

I013 - Benchmarks for Difficult-to-Sequence Genes and Structural Variants

Justin Zook, PhD, National Inst of Standards & Tech, Gaithersburg, MD, USA

I040 - Machine Learning Applications for Patient Testing: Computational Assessment of MSI by NGS in the Clinical Laboratory

Gregory Omerza, PhD, The Jackson Laboratory, Farmington, CT, USA

I020 - Mixed Reality for a Precision Medicine Laboratory: the Future is Now!

Andrea Sboner, PhD, Weill Cornell Medicine, New York, NY, USA

I004 - Impact of Next Generation Sequencing Panel Composition on Tumor Mutation Burden Calculation – In Silico Comparison of Frequently Utilized Panels

Nicholas Bevins, MD, PhD, University of California at San Diego, San Diego, CA, USA

Session Description: Platform presentations of selected Informatics abstracts.

Session Objectives:

  • Analyze platform presentations of abstracts highlighted by the Informatics Subdivision leadership as particularly significant.
  • Evaluate the scientific merit and significance of these selected studies through further discussion with the authors.

Duration: 1.25 hrs

Recording Date: November 9, 2019

CME/CMLE credit: 1.25 hr

SAM credit: 1.25 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Informatics Platform Presentations
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

ST132 - The Impact of Clinical Molecular Testing and Precision Medicine in Thyroid Cancer

Dora Dias-Santagata, PhD, FACMG, Massachusetts General Hospital - Harvard Medical School, Boston, MA, USA

ST009 - Improved Detection of MET Exon 14 Skipping Mutations in Lung Adenocarcinoma with Combined DNA/RNA Testing and Refined Analysis Methods

David Manthei, MD, PhD, University of Michigan, Department of Pathology, Ann Arbor, MI, USA

ST010 - Detection of Point Mutations in Paediatric Low Grade Glioma (PLGG) and Diffuse Intrinsic Pontine Glioma (DIPG) Patients: Validation of a Novel Liquid Biopsy Assay

Monique Johnson, MSc, The Hospital for Sick Children, Toronto, Ontario, Canada

ST015 - Clonal hematopoiesis mutations in plasma cfDNA RAS/BRAF genotyping of metastatic colorectal cancer

Fei Huang, Zhongshan Hospital, Fudan University, Shanghai, China

ST094 - STK11 Loss of Function Variants Mediate Immune Evasion in NSCLC via Dysregulation of the FAK/Hippo Signaling Axis and Subsequent Alterations in Tumor-Intrinsic Cytokine Expression

Liam Donnelly, MD, University of Vermont Medical Center, Burlington, VT, USA

Session Description: Platform presentations of selected Solid Tumors abstracts.

Session Objectives:

  • Analyze presentations of abstracts highlighted by the Solid Tumors Subdivision leadership as particularly significant.
  • Evaluate the scientific merit and significance of these selected studies through further discussion with the authors.

Duration: 1.25 hrs

Recording Date: November 9, 2019

CME/CMLE credit: 1.25 hr

SAM credit: 1.25 hr

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Solid Tumor Platform Presentation
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

TT011 - A Comprehensive Assessment of onco-panel sequencing across multiple laboratories and technologies

Joshua Xu

TT066 - Variants Reported by Tumor-Only Clinical Oncology NGS Testing Are Frequently Found in the Germline of Pediatric Patients

Azhar Saeed, MD, MSc, University of Kansas Medical Center, Kansas City, KS, USA

TT071 - EXaCT-2: Augmented Whole Exome Sequencing Optimized for Clinical Testing in Oncology

Duane Hassane, PhD, Weill Cornell Medicine, New York, NY, USA

TT055 - Digital Methylation Specific Multiplex Ligation-Dependent Probe Amplification: A Novel MLPA Based Technique for Assessing Promoter Methylation Status in Cancer

Jan Smout, MSc, MRC Holland, Amsterdam, Netherlands

Session Description: Platform presentations of selected Technical Topics abstracts.

Session Objectives:

  • Analyze platform presentations of abstracts highlighted by the Technical Topics leadership as particularly significant.
  • Evaluate the scientific merit and significance of these selected studies through further discussion with the authors.

Duration: 1.00 hr

Recording Date: November 9, 2019

CME/CMLE credit: 0.75 hr (Jan Smout's talk is not eligible for CME, CMLE)

SAM credit: 0.75 hr (Jan Smout's talk is not eligible for SAM)

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Technical Topics Platform Presentations
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00

MRD in AML - Promises, Problems and Perspectives

Eric Duncavage, MD, Washington University, Saint Louis, MO, USA

Session Description: Numerous studies have demonstrated the value of measurable residual disease (MRD) as a prognostic marker in patients with acute leukemia. While many markers have been well-validated for this approach such as NPM1 and specific recurrent fusions, some markers such as those associated with clonal hematopoiesis remain challenging. This session will discuss advances in the methods of MRD detection in acute myeloid leukemia (AML) and highlight some of the pitfalls.

Session Objectives:

  • Describe different methods used to monitor acute myeloid leukemia following therapy.
  • Discuss potential pitfalls associated with these methods.
  • Synthesize an integrated approach to monitor therapy response in acute myeloid leukemia.

Duration: 1.00 hr

Recording Date: November 9, 2019

CME/CMLE credit: 1.00 hr 

SAM credit:not available

Last day to purchase course and claim CE creditDecember 24, 2022

ProductAddPrice
Duncavage
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $189.00
Wednesday November 6, 2019

This bonus feature is included only with the purchase of the entire 2019 AMP Annual Meeting and Expo Recording. The course was held on Wednesday, November 6, 2019. It includes the recorded lecture portion of the Molecular Pathology Outreach Course and associated course materials. 

DESCRIPTION:

This course is designed to bring you up to speed in molecular pathology. The course covers current molecular hot topics, and then preanalytical variables that impact molecular testing, followed by an overview of current molecular technology including the application of novel technologies such as next generation sequencing and informatics. 

LEARNING OBJECTIVES:

  • Identify common preanalytical variables that impact molecular testing.
  • Select the most appropriate clinical applications for PCR, non-PCR based amplification and array platforms.
  • Discuss the methodologic and clinical considerations of when to implement testing by NGS.
  • Compare and contrast methods of single nucleotide variant detection, copy number detection, and structural variant (fusions) detection by NGS and other related platforms (for CNVs).

TARGET AUDIENCE

Community pathologists, pathologists new to molecular, trainees, and technologists

Duration: 3.00hrs

Recording Date: November 6, 2019

CME/CMLE credit: 2.50 hr 

SAM credit: 2.50 hr 

Last day to purchase course and claim CE creditDecember 24, 2022

Not Available for Individual Purchase
Individual topic purchase: Selected
Products
AM19 Recording
AMP Regular Member: $450.00
AMP Technologist Member: $450.00
AMP Associate Member: $450.00
Non-member Price: $649.00